Cantor Fitzgerald Keeps Their Buy Rating on Sabra Healthcare REIT

By Ryan Adsit

In a report released today, Joseph France from Cantor Fitzgerald reiterated a Buy rating on Sabra Healthcare REIT (NASDAQ: SBRA), with a price target of $30. The company’s shares opened today at $24.15.

France noted:

“Potential tweaks could improve coverage. Based on our preliminary analysis of CCP’s numbers, two of its larger operators with poor coverage can be significantly improved while SBRA achieves significant accretion. SBRA has not committed to any particular plan of action, but boosting the SNF portfolio’s coverage to 1.4x from the current 1.2x might be achievable at a cost of $25-$30 million.”

According to, France is a 5-star analyst with an average return of 13.8% and a 57.6% success rate. France covers the Healthcare sector, focusing on stocks such as CRH Medical Corporation, Five Star Quality Care, and WellCare Health Plans.

Sabra Healthcare REIT has an analyst consensus of Moderate Buy, with a price target consensus of $28.

The company has a one year high of $29.10 and a one year low of $19.30. Currently, Sabra Healthcare REIT has an average volume of 798.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sabra Health Care REIT, Inc. operates as a self-administered, self-managed real estate investment trust. Through its subsidiaries it owns and invests in real estate serving the healthcare industry. Its primary business consists of acquiring, financing, and owning real estate property to be leased to third party tenants in the healthcare sector throughout the United States and Canada. The company was founded on May 10, 2010 and is headquartered in Irvine, CA.